Actavis Labs Florida, Inc. secured FDA approval for its generic sildenafil citrate tablets (20 mg), clearing the way for a competitive launch in the Pulmonary Arterial Hypertension market. This approval positions the company to capture market share and generate additional revenue ahead of the brand-name drug’s eventual loss of exclusivity.